Recently, both genome-wide association studies (GWAS) and candidate gene studies have reported that CDKN2BAS (cyclin-dependent kinase inhibitor 2B antisense RNA) is a risk gene for CHD susceptibility [6–8]. This evidence concerns the gene CDKN2B-AS1 and coronary artery disorder.